recent
year
use
infe
antibiot
growth
diseas
prevent
livestock
product
sever
scrutini
use
misus
infe
antibiot
led
problem
drug
residu
anim
product
increas
bacteri
resist
chicken
egg
yolk
antibodi
igi
attract
consider
attent
altern
antibiot
maintain
swine
health
perform
oral
administr
igi
possess
mani
advantag
mammalian
igg
costeffect
conveni
high
yield
review
present
overview
potenti
use
igi
immunotherapi
prevent
treatment
swine
diarrhea
diseas
specul
futur
igi
technolog
includ
review
potenti
applic
igi
control
enter
infect
either
bacteri
viral
origin
enterotoxigen
escherichia
coli
salmonella
spp
rotaviru
porcin
transmiss
gastroenter
viru
porcin
epidem
diarrhea
viru
potenti
obstacl
adopt
igi
technolog
also
discuss
intern
licens
http
permit
unrestrict
use
distribut
reproduct
medium
provid
give
appropri
credit
origin
author
sourc
provid
link
creativ
common
licens
indic
chang
made
creativ
common
public
domain
dedic
waiver
antibiot
wide
use
swine
industri
year
efficaci
antibiot
increas
growth
rate
improv
feed
util
reduc
incid
diseas
well
document
gener
subtherapeut
level
antibiot
swine
diet
increas
growth
rate
averag
weanl
pig
grow
pig
growingfinish
pig
addit
antibiot
also
use
diseas
prevent
prophylact
dose
treatment
therapeut
dose
howev
seriou
concern
arisen
regard
potenti
risk
human
health
includ
drug
residu
meat
product
increas
bacteri
resist
due
use
misus
infe
antibiot
result
european
union
total
ban
use
antibiot
growth
promot
sinc
januari
us
food
administr
fda
phase
nonmed
antibiot
use
livestock
sinc
decemb
diarrheal
diseas
frequent
caus
heavi
econom
loss
swine
produc
major
challeng
current
face
swine
industri
develop
altern
mean
control
diarrhea
young
pig
particularli
neonat
earlywean
piglet
cost
effect
also
allow
sustain
pork
product
past
two
decad
varieti
materi
test
effect
altern
antibiot
maintain
swine
health
perform
wide
research
altern
includ
enzym
organ
acid
proand
prebiot
herbal
extract
neutraceut
copper
zinc
howev
altern
produc
limit
growth
promot
protect
pathogen
recent
egg
yolk
antibodi
gener
refer
igi
attract
consider
interest
altern
antibiot
growth
promot
presenc
diseas
caus
organ
igi
possess
larg
number
advantag
mammalian
igg
costeffect
conveni
high
yield
oral
administr
specif
igi
antibodi
shown
highli
effect
varieti
intestin
pathogen
caus
diarrhea
anim
human
enterotoxigen
escherichia
coli
etec
salmonella
spp
bovin
human
rotavirus
bovin
coronaviru
porcin
transmiss
gastroenter
viru
tgev
porcin
epidem
diarrhea
viru
pedv
follow
brief
descript
igi
technolog
advantag
igi
review
focu
potenti
use
specif
igi
product
enhanc
swine
product
discuss
potenti
obstacl
adopt
igi
technolog
describ
year
ago
klemper
first
demonstr
avian
matern
antibodi
transfer
serum
egg
yolk
order
protect
develop
embryo
potenti
pathogen
time
scientif
applic
knowledg
howev
anim
welfar
becam
matter
seriou
ethic
concern
scientif
commun
result
klemper
began
receiv
interest
particularli
sinc
sinc
igi
technolog
ie
product
use
igi
becom
intern
accept
practic
european
centr
valid
altern
method
ecvam
workshop
strongli
recommend
igi
use
altern
mammalian
antibodi
igi
technolog
approv
altern
method
support
anim
welfar
veterinari
offic
swiss
govern
offic
detail
concern
product
specif
igi
review
schade
et
al
briefli
order
produc
specif
igi
antibodi
lay
hen
immun
specif
foreign
pathogen
induc
immun
respons
includ
product
antibodi
activ
specif
diseas
condit
antibodi
transfer
egg
yolk
deposit
larg
quantiti
booster
immun
usual
given
ensur
continu
transfer
antibodi
hen
serum
egg
yolk
antibodi
extract
egg
yolk
process
administ
directli
anim
incorpor
diet
antibodi
administ
sever
form
includ
whole
egg
powder
whole
yolk
powder
watersolubl
fraction
powder
purifi
igi
antibodi
product
titer
develop
result
immun
predict
variabl
influenc
immun
includ
antigen
dose
mw
type
adjuv
use
rout
immun
immun
frequenc
chicken
hous
condit
age
breed
egg
lay
capac
use
chicken
immun
host
antibodi
product
provid
number
advantag
product
method
use
mammal
signific
advantag
egg
collect
noninvas
compar
stress
bleed
anim
obtain
serum
addit
high
longlast
titer
produc
chicken
reduc
need
frequent
booster
inject
anoth
advantag
product
igi
antibodi
highli
conserv
mammalian
protein
success
chicken
mammal
requir
much
less
antigen
induc
effici
immun
respons
due
phylogenet
distanc
chicken
mammal
hen
consid
small
factori
antibodi
product
one
hen
produc
g
total
igi
per
year
specif
antibodi
extraordinari
quantiti
equival
product
rabbit
cours
year
cost
maintain
lay
hen
also
lower
mammal
rabbit
therefor
egg
yolk
offer
hygien
costeffici
conveni
rich
sourc
antibodi
compar
tradit
product
method
use
mammal
contrast
antibiot
use
igi
environmentallyfriendli
elicit
undesir
side
effect
diseas
resist
toxic
residu
term
function
unlik
mammalian
igg
igi
activ
mammalian
complement
also
interact
mammalian
fc
complement
receptor
well
igi
bind
protein
protein
g
rheumatoid
factor
differ
provid
great
advantag
success
applic
igi
technolog
mani
research
area
diagnost
antibioticaltern
therapi
xenotransplant
exact
mechan
igi
counteract
pathogen
activ
determin
howev
sever
mechan
propos
xu
et
al
includ
agglutin
bacteria
inhibit
adhes
well
opson
follow
phagocytosi
toxin
neutral
among
inhibit
adhes
consid
primari
mechan
specif
igi
function
briefli
igi
antibodi
gener
intestin
diseas
caus
organ
may
reduc
incid
diseas
prevent
attach
pathogen
intestin
block
mucos
receptor
interf
bind
mucin
neutral
colon
factor
outer
membran
protein
lipopolysaccharid
fimbria
pili
flagella
possibl
primari
mode
action
igi
protect
pig
e
coli
induc
diarrhea
illustr
fig
diarrhoea
neonat
postwean
pig
caus
number
caus
agent
becom
seriou
problem
swine
industri
due
trend
toward
larg
intens
herd
earli
wean
ie
rather
day
age
potenti
applic
use
oral
administ
igi
control
enter
infect
either
bacteri
viral
origin
piglet
studi
length
summar
tabl
enterotoxigen
escherichia
coli
diarrhea
due
enterotoxigen
escherichia
coli
etec
far
common
enter
colibacillosi
encount
neonat
postwean
pig
etec
caus
diarrhea
piglet
colon
small
intestin
thereaft
product
either
one
two
enterotoxin
name
heatlabil
enterotoxin
lt
heatstabl
enterotoxin
st
induc
massiv
fluid
electrolyt
secret
gut
lumen
strain
e
coli
associ
intestin
colon
caus
sever
diarrhea
express
fimbrial
adhes
fimbrial
adhes
mediat
adhes
e
coli
epitheli
mucosa
line
intestin
therebi
contribut
virul
among
differ
etec
express
fimbrial
antigen
preval
form
caus
e
coli
infect
worldwid
estim
etec
respons
half
piglet
mortal
occur
annual
oral
administr
igi
offer
potenti
prophylact
therapeut
approach
control
e
coliinduc
diarrhea
piglet
igi
shown
success
control
intestin
infect
e
coli
young
pig
yokoyama
et
al
show
oral
administ
crude
igi
watersolubl
fraction
gener
e
coli
fimbria
protect
infect
three
homolog
strain
e
coli
dosedepend
manner
colostrumdepriv
piglet
vitro
e
coli
strain
adher
equal
porcin
epitheli
cell
duodenum
ileum
fail
presenc
homolog
antifimbri
igi
group
marquardt
univers
manitoba
canada
carri
excel
studi
passiv
protect
effect
igi
etec
fimbria
neonat
earlywean
piglet
anim
feed
studi
old
pig
oral
challeng
high
dose
etec
h
experi
oral
administ
crude
igi
watersolubl
fraction
three
time
day
two
consecut
day
first
e
coli
challeng
control
piglet
treat
igi
nonimmun
hen
sever
diarrhea
within
h
lost
weight
pig
die
within
h
infect
contrast
pig
given
igi
immun
hen
exhibit
sign
diarrhea
h
treatment
posit
weight
gain
furthermor
group
perform
studi
practic
use
igi
field
trial
experi
show
suppress
incid
sever
diarrhea
wean
piglet
fed
specif
igi
powder
much
lower
fed
commerci
diet
contain
antibiot
number
pig
studi
larg
would
desir
repeat
studi
greater
number
anim
anoth
studi
e
coli
shown
antibodi
diminish
incid
diarrhea
death
wean
piglet
infect
e
coli
zuniga
et
al
also
report
wean
pig
fed
basal
feed
plu
ww
egg
powder
igi
antibodi
fimbrial
variant
fulli
protect
pig
challeng
e
coli
addit
reduc
incid
sever
piglet
diarrhea
sever
studi
shown
igi
growth
promot
effect
earlywean
pig
similar
spraydri
anim
plasma
spraydri
porcin
plasma
tabl
show
result
experi
perform
pig
fed
specif
antibodi
compar
pig
fed
diet
supplement
zinc
oxid
fumar
acid
antibiot
oral
etec
challeng
four
feed
addit
success
increas
pig
perform
compar
unsuppl
pig
signific
reduct
observ
scour
score
piglet
mortal
experi
igi
equal
antibiot
enhanc
pig
perform
tabl
show
effect
ad
egg
yolk
contain
specif
antibodi
egg
eggexchang
spray
dri
porcin
plasma
cornsoybean
mealbas
con
diet
perform
plasma
urea
weight
pancrea
wean
pig
challeng
etec
challeng
result
show
addit
egg
con
diet
reduc
plasma
urea
nitrogen
concentr
increas
feed
intak
tend
increas
weight
gain
phase
ii
studi
indic
inclus
egg
diet
pig
immedi
wean
significantli
affect
futur
growth
perform
unfortun
limit
number
pig
use
studi
repeat
greater
number
would
certainli
welcom
although
adhesinmedi
colon
precondit
etec
pathogenesi
enterotoxin
thought
central
virul
determin
lead
diarrhea
diseas
may
also
play
role
colon
process
therefor
ideal
protect
agent
etec
infect
includ
protect
adhesin
antigen
enterotoxin
contrast
ltb
sta
enterotoxin
sta
stb
poorli
immunogen
small
size
attain
immunogen
coupl
chemic
genet
appropri
carrier
order
make
use
toxoid
construct
polyval
enterotoxin
staltbstb
dna
protein
vaccin
endow
immunogen
sta
stb
lay
hen
immun
dna
vaccin
obtain
antitox
antibodi
egg
yolk
confirm
indirect
elisa
polyval
dna
vaccin
pcistaltbstb
express
staltbstb
fusion
peptid
vitro
cultur
hela
cell
egg
yolk
antibodi
abl
neutral
natur
toxic
sta
ltb
highest
dilut
suckl
mous
assay
result
indic
recombin
staltbstb
protein
potenti
serv
effect
conveni
polyval
toxoid
provid
broad
protect
etecinduc
diarrhea
studi
conduct
mice
piglet
studi
conduct
confirm
find
salmonella
infect
recogn
one
common
foodborn
diseas
human
caus
million
case
estim
econom
impact
billion
year
unit
state
diseas
occur
via
foodborn
transmiss
anim
contact
environment
spread
farm
owusuasiedu
et
al
anim
like
sourc
human
salmonellosi
therefor
import
control
diseas
reduc
product
loss
domest
livestock
also
prevent
transmiss
human
food
chain
salmonella
speci
enteritidi
typhimurium
particular
thought
major
agent
human
salmonellosi
nonhost
serotyp
caus
diseas
syndrom
like
gastroenter
system
infecti
wide
rang
anim
speci
includ
human
studi
yokoyama
et
al
investig
efficaci
igi
antibodi
specif
outer
membran
protein
omp
lipopolysaccharid
lp
flagella
fla
control
typhimurium
enteritidi
treat
mice
oral
appropri
placebo
purifi
igi
follow
challeng
enteritidi
antibodi
treatment
result
surviv
rate
use
omp
lp
flaspecif
antibodi
contrast
surviv
rate
control
mice
typhimurium
trial
surviv
rate
use
omp
lp
flaspecif
antibodi
contrast
control
mice
preliminari
result
suggest
antibodi
specif
salmonella
protein
control
salmonellosi
oral
administr
mice
studi
pig
report
unfortun
report
similar
benefit
igi
found
mice
obtain
pig
mathew
et
al
found
feed
egg
yolk
powder
contain
antisalmonella
igi
antibodi
may
particularli
effect
reduc
salmonella
shed
pig
experi
specif
egg
yolk
powder
deriv
chicken
challeng
purifi
salmonella
typhimurium
antigen
fimbrial
protein
omp
lp
includ
swine
feed
treatment
provid
begin
day
experi
pig
challeng
salmonella
typhimurium
day
fecal
sampl
collect
day
determin
shed
salmonella
result
show
infe
igi
antibodi
diminish
shed
salmonella
inferior
antibiot
treatment
failur
igi
improv
perform
suspect
due
fact
invas
natur
salmonella
allow
organ
bypass
gut
dietari
treatment
move
vascular
andor
lymphat
rout
directli
colon
howev
avail
data
still
limit
allow
reliabl
conclus
regard
possibl
efficaci
igi
control
salmonella
infect
swine
porcin
transmiss
gastroenter
viru
tgev
porcin
coronaviru
caus
highli
contagi
enter
infect
swine
age
infect
piglet
develop
signific
clinic
sign
includ
vomit
emaci
sever
diarrhea
diseas
especi
sever
anim
less
week
old
mortal
nearli
lack
success
vaccin
prevent
tge
outbreak
diseas
occur
frequent
swine
farm
shown
specif
igi
great
potenti
altern
prophylact
approach
like
colostr
antibodi
tgev
prophylact
efficaci
experi
oral
administr
igi
significantli
increas
newborn
piglet
surviv
rate
challeng
exposur
compar
control
wherea
therapeut
effect
demonstr
mortal
dramat
reduc
oral
administ
igi
two
farm
show
tgev
posit
result
unfortun
piglet
perform
monitor
studi
porcin
epidem
diarrhea
viru
pedv
anoth
import
enter
viral
pathogen
respons
neonat
piglet
diarrhea
although
clinic
symptom
pedv
infect
similar
tgev
infect
pedv
antigen
differ
tgev
epidemiolog
observ
indic
spread
diseas
seem
slower
rather
persist
compar
tgev
outbreak
shown
igi
altern
method
confer
protect
piglet
pedv
igi
found
reduc
mortal
piglet
challeng
exposur
field
applic
igi
three
farm
also
reveal
surviv
rate
increas
significantli
pig
treat
igi
compar
control
group
rotaviru
major
pathogen
infecti
gastroenter
children
infant
also
domest
anim
human
alon
estim
rotaviru
infect
result
sever
million
death
year
anim
also
serious
affect
viru
rotaviru
calv
pig
mice
foal
infant
human
lamb
chicken
turkey
antigen
relat
therefor
appropri
antirotaviru
antibodi
react
viru
present
speci
igi
shown
success
control
intestin
infect
rotaviru
newborn
calv
mice
studi
pig
report
similar
posit
result
obtain
passiv
treatment
base
human
rotaviru
specif
igi
antibodi
prevent
gnotobiot
piglet
develop
diarrhea
caus
preval
strain
wa
hrv
also
significantli
reduc
amount
infecti
viru
shed
compar
neg
control
group
mani
obstacl
limit
use
igi
control
diarrhea
diseas
swine
import
issu
need
address
follow
stabil
igi
gastrointestin
tract
fed
swine
although
benefici
effect
pathogenspecif
igi
anim
known
year
result
experiment
applic
antibodi
swine
alway
consist
sever
report
igi
fail
improv
pig
perform
like
explan
failur
treatment
antibodi
fail
surviv
passag
gastrointestin
tract
result
suscept
proteolysi
igi
glycoprotein
sensit
denatur
condit
protein
report
igi
fairli
resist
digest
intestin
proteas
activ
igi
decreas
ph
lower
almost
complet
lost
irrevers
chang
ph
addit
inactiv
low
ph
enhanc
presenc
pepsin
contrast
young
pig
stomach
older
pig
low
ph
pepsin
therefor
igi
may
effect
control
postwean
e
coli
diarrhea
older
anim
yokoyama
et
al
excel
studi
detect
rate
igi
passag
gastrointestin
tract
pig
abil
retain
activ
differ
section
tract
result
demonstr
igi
readili
absorb
within
h
newli
born
pig
igi
serum
halflif
day
newborn
pig
shorter
report
serum
halflif
day
homolog
igg
colostr
antibodi
amount
igi
absorb
circul
administ
pig
decreas
increas
age
pig
sinc
primari
target
site
igi
small
intestin
order
function
must
abl
surviv
passag
harsh
environment
condit
found
stomach
microencapsul
techniqu
develop
protect
igi
gastric
inactiv
tabl
show
result
experi
chitosanalgin
microcapsul
use
oral
deliveri
egg
yolk
immunoglobulin
wean
pig
challeng
enterotoxigen
e
coli
percentag
pig
diarrhea
h
treatment
diarrhea
score
improv
pig
receiv
encapsul
igi
compar
non
pig
except
neg
control
oral
challeng
ml
viabl
e
coli
organ
cfuml
per
pig
time
h
challeng
pig
left
untreat
posit
control
treat
three
time
h
bacteri
challeng
first
day
twice
day
two
consecut
day
time
g
nonencapsul
igi
g
microencapsul
igi
equival
g
igi
g
aureomycin
diarrhea
weight
gain
assess
day
challeng
fc
score
mean
fecal
consist
score
normal
soft
fece
mild
diarrhea
sever
diarrhea
pig
fecal
score
consid
diarrhea
mean
column
follow
letter
differ
p
encapsul
igi
addit
weight
gain
three
day
period
significantli
higher
pig
receiv
encapsul
igi
compar
nonencapsul
igi
encapsul
nonencapsul
igi
treatment
numer
superior
aureomycin
treat
group
howev
process
undoubtedli
add
addit
cost
addit
studi
need
microencapsul
appli
commerci
condit
stabil
igi
subject
feed
process
eggyolk
antibodi
administr
young
pig
either
prevent
prophylact
treatment
therapeut
treatment
infect
occur
appear
ad
antibodi
swine
feed
form
whole
egg
powder
whole
yolk
powder
may
practic
method
inclus
igi
prevent
prophylact
treatment
known
igi
antibodi
toler
heatbas
feed
process
techniqu
pellet
presum
stabil
igi
antibodi
would
similar
enzym
stabil
would
greatli
influenc
temperatur
durat
heat
treatment
cool
period
well
moistur
content
diet
well
known
chang
moistur
content
dri
matter
dramat
decreas
stabil
protein
heat
high
temperatur
preliminari
studi
marquardt
et
al
demonstr
low
temperatur
steam
pellet
reduc
antibodi
titer
studi
need
carri
problem
igi
attract
effect
altern
approach
antibiot
due
high
specif
note
swine
expos
mani
infecti
agent
commerci
oper
therefor
swine
industri
benefit
igi
antibodi
produc
mixtur
common
diseas
caus
organ
rather
one
specif
diseas
approach
work
well
may
help
justifi
extent
commerci
applic
antibodi
efficaci
igi
gastrointestin
tract
relat
two
factor
name
dose
antibodi
concentr
pathogen
result
yokoyama
et
al
demonstr
antibodi
pass
digest
system
within
rel
short
period
time
slightli
h
addit
reach
section
gastrointestin
tract
less
h
suppli
antibodi
intestin
must
suffici
high
prevent
bind
pathogen
intestin
receptor
antibodi
must
also
continu
nearli
continu
avail
intestin
studi
marquardt
et
al
show
g
per
day
per
piglet
suffici
prevent
diarrhea
induc
infect
etec
addit
eggyolk
antibodi
diet
prevent
diarrhea
commerci
farm
howev
consider
amount
addit
research
must
carri
identifi
best
antigen
use
appropri
prevent
treatment
protocol
control
intestin
pathogen
differ
strain
e
coli
present
product
cost
high
qualiti
igi
antibodi
higher
cost
routin
antibiot
inclus
therefor
develop
method
largescal
product
igi
produc
high
recoveri
puriti
igi
need
method
simpl
econom
requir
chemic
addit
consensu
suitabl
igi
extract
method
commerci
applic
requir
studi
oral
administr
specif
igi
appear
consider
potenti
mean
control
diarrhea
diseas
exert
growthpromot
activ
swine
igi
technolog
probabl
provid
best
altern
antibiot
advantag
igi
control
swine
diseas
highli
effect
highli
costeffect
small
amount
antibodi
requir
per
pig
collect
egg
noninvas
treatment
safe
live
organ
use
procedur
environment
friendli
toxic
residu
produc
develop
resist
treatment
use
control
mani
differ
type
pathogen
